Pharmacologic Enhancement of Gallium-67 Tumor-to-blood Ratios for EMT-6 Sarcoma (BALB/c Mice)
Authors
Affiliations
At various intervals after intravenous injection of carrier-free 67Ga-citrate, iron dextrane or deferoxamine mesylate was injected into EMT-6 tumor-bearing BALB/c mice. After treatment, rapid clearance of 67Ga from soft tissues was observed. Tumor uptake was not greatly affected, and so increased tumor-to-blood ratios were observed. The authors conclude that these drugs can enhance target-to-nontarget uptake ratios for tumors.
Deferoxamine mesylate enhancement of 67Ga tumor-to-blood ratios and tumor imaging.
Koizumi K, Tonami N, Hisada K Eur J Nucl Med. 1982; 7(5):229-33.
PMID: 6954069 DOI: 10.1007/BF00256470.
Tomographic gallium-67 citrate scanning. Useful new surveillance for metastatic melanoma.
Kirkwood J, Myers J, Vlock D, Neumann R, Ariyan S, Gottschalk A Ann Surg. 1983; 198(1):102-7.
PMID: 6859984 PMC: 1352941. DOI: 10.1097/00000658-198307000-00020.
Relative tumour enhancement of 67Ga uptake by desferrioxamine.
Hammersley P Eur J Nucl Med. 1984; 9(10):461-71.
PMID: 6595115 DOI: 10.1007/BF00563171.
Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent.
Eccles S, Dean C, Coghlan G Eur J Nucl Med. 1985; 11(6-7):240-5.
PMID: 4076230 DOI: 10.1007/BF00279077.
Gallium-67 scintigraphy in patients with hemochromatosis treated by deferoxamine.
Nagamachi S, Hoshi H, Jinnouchi S, Ono S, Watanabe K Ann Nucl Med. 1988; 2(1):35-9.
PMID: 3275103 DOI: 10.1007/BF03164584.